Literature DB >> 24661406

Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges.

Etsuko Hashimoto1, Katsutoshi Tokushige, Jurgen Ludwig.   

Abstract

The high prevalence of non-alcoholic fatty liver disease (NAFLD) has made the condition an important public health issue. Two clinical entities are manifestations of NAFLD, namely, non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). The former tends to be benign and non-progressive while the latter can progress to cirrhosis, which in rare cases gives rise to hepatocellular carcinoma. The diagnosis of NAFLD is based on: (i) a history of no or limited daily alcohol intake (<20 g for women and <30 g for men); (ii) presence of hepatic steatosis by imaging or by histology; and (iii) exclusion of other liver diseases. NAFL is defined histologically by the presence of bland, primarily macrovesicular, hepatocellular fatty change, while NASH features fatty change with inflammation and evidence of hepatocyte injury, such as ballooning degeneration. Presence of fibrosis is a sign of chronicity. Thus, the diagnosis of NAFL/NASH rests on clinicopathological criteria; it always requires both clinical and biopsy-based information. NAFLD could be both the result and the cause of metabolic syndrome, with a vicious cycle operating between these conditions. Remaining challenges are: (i) the lack of a clear threshold alcohol intake for defining "non-alcoholic"; (ii) a lacking consensus for the classification of fatty liver disease; and (iii) absence of a histological definition of NASH, which currently remains the gold standard for the diagnosis. Further challenges include the overlap of the criteria for NAFLD and alcoholic liver disease as many obese individuals also consume considerable volumes of alcohol.
© 2014 The Japan Society of Hepatology.

Entities:  

Keywords:  classification; clinical diagnosis; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; pathological diagnosis; steatohepatitis

Year:  2014        PMID: 24661406     DOI: 10.1111/hepr.12333

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  24 in total

1.  Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver.

Authors:  Rohitash Jamwal; Suzanne M de la Monte; Ken Ogasawara; Sravani Adusumalli; Benjamin B Barlock; Fatemeh Akhlaghi
Journal:  Mol Pharm       Date:  2018-06-11       Impact factor: 4.939

2.  Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.

Authors:  Kazuto Tajiri; Kengo Kawai; Toshiro Sugiyama
Journal:  J Gastroenterol       Date:  2016-10-27       Impact factor: 7.527

3.  Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD).

Authors:  Cathrin Sellmann; Cheng Jun Jin; Anna Janina Engstler; Jean-Pascal De Bandt; Ina Bergheim
Journal:  Eur J Nutr       Date:  2016-08-05       Impact factor: 5.614

4.  Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease.

Authors:  Nozomu Wada; Akinobu Takaki; Fusao Ikeda; Tetsuya Yasunaka; Masahiro Onji; Kazuhiro Nouso; Atsuko Nakatsuka; Jun Wada; Kazuko Koike; Koji Miyahara; Hidenori Shiraha; Kazuhide Yamamoto; Hiroyuki Okada
Journal:  Hepatol Int       Date:  2016-11-08       Impact factor: 6.047

5.  Diabetes and hepatocellular carcinoma risks in patients with nonalcoholic steatohepatitis related cirrhosis.

Authors:  Chien-Hsieh Chiang; Kuo-Chin Huang
Journal:  Hepatobiliary Surg Nutr       Date:  2020-06       Impact factor: 7.293

6.  Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up.

Authors:  Takayoshi Nishioka; Shoji Kubo; Shogo Tanaka; Kenichi Wakasa; Shigekazu Takemura; Masahiko Kinoshita; Genya Hamano; Yuko Kuwae; Toshihiko Shibata; Shigefumi Suehiro
Journal:  Liver Cancer       Date:  2016-03-17       Impact factor: 11.740

7.  Levels of abdominal adipose tissue and metabolic-associated fatty liver disease (MAFLD) in middle age according to average fast-food intake over the preceding 25 years: the CARDIA Study.

Authors:  Andrew O Odegaard; David R Jacobs; Lisa B Van Wagner; Mark A Pereira
Journal:  Am J Clin Nutr       Date:  2022-07-06       Impact factor: 8.472

Review 8.  Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.

Authors:  Manoj K Mahapatra; Muthukumar Karuppasamy; Biswa M Sahoo
Journal:  Pharm Res       Date:  2022-06-01       Impact factor: 4.580

Review 9.  Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy.

Authors:  Baron Bechtold; John Clarke
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

Review 10.  Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.

Authors:  Yueqi Zhang; Hongbing Wang; Hua Xiao
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.